Job of the week: Clinical Trial Liaison Manager

We are recruiting for a Clinical Trial Liaison Manager to join a very successful drug development company to support a global Phase II respiratory study.

  • A fantastic and rare opportunity to join an innovative and successful global drug development company
  • This role will be perfect for someone with a mixture of clinical operations and liaison experience.
  • Home based from anywhere in Europe or the US.
  • This role will involve working closely with the sponsor, CRO and investigator sites to ensure the smooth running of clinical studies, ensuring that everyone involved is trained to the highest standards, that sites are inspection ready at all times and that any issues are resolved promptly and appropriately.

Read the full job description or apply here

Posted in Articles, General, Homepage, Job of the Week, News

5 things to avoid including in your CV

It is no secret that the job market is highly competitive, and that it is a tough challenge nowadays just trying to get your CV noticed. On average, a recruiter will scan a CV for less than 20 seconds – leaving you very little time to impress them. It is therefore crucial to get your CV right and make those precious seconds count.

Here is a short list of things NOT to include if you want to make that lasting impression.


  1. Avoid overused buzzwords

We often hear about the top keywords to include in your CV to get noticed. But ironically, with everyone using them, recruiters read these “buzzwords” over and over again and they end up having no meaning.

According to LinkedIn, the most used buzzword on people’s profiles is “motivated”. “Specialised” is another word that appears on most CVs, closely followed by “leadership” and “experienced”.

Other words that appear far too often are “successful”, “passionate” and “enthusiastic”.

In a previous article we suggested different ways of saying these most common buzzwords – see here. For example, instead of using “motivated” why not use words such as inspired, enthused or determined to achieve success?


  1. Avoid generic terminology

Other phrases to avoid at all costs are vague terminologies such as “responsible for”, “thought leadership” or “results-driven”.

Being “responsible for a team” doesn’t give much proof of your capabilities or what role you played. Instead, use decisive verbs such as “managed” or “directed” with facts and figures.


  1. Show, don’t tell

It is meaningless to claim something without the facts and figures to back it up.

Instead of using keywords, describe your best examples. Explain what drives you, what inspires you the most in your job or your best achievements. This will help recruiters get a better insight on who you are and what you can bring to the table.

A good tactic is to use numbers alongside buzzwords to show your value. This will get your CV noticed and give you credibility.

For example – “I managed a team of 10 people and successfully launched X bringing in a revenue of Y over 3 years”.


  1. Remove any irrelevant experience

As mentioned previously, a recruiter will spend less than 20 seconds looking at your CV, so make sure all the information you provide is relevant to the role you are applying for. Keep your CV to the point.


  1. Remove the unnecessary

And finally, remove any other information from your CV that is unnecessary at this stage of the application process. Here is a list of a few items that often appear on CVs and have no place being there.

  • The words “References available upon request “
  • The words “Salary is negotiable “
  • More than one address
  • A headshot

Stand out from the crowd, think about what experiences you have which are relevant to the role and set you aside from the crowd. Recruiters don’t want to see yet another generic CV, they want to see a concise CV full of examples and proof of your capabilities.

For more advice on how to improve your CV, contact us.


Posted in Candidates, Careers Advice, General, News

The Australian flu – why can’t we control it?


The Australian flu epidemic attacked the southern hemisphere in the winter of 2017 and has now, as feared, come to the UK and is rapidly causing a state of chaos for doctors, hospitals and the NHS in general.

Britain is facing one of the worst flu crises in 20 years. It is estimated that one in five people being hospitalised with flu is suffering from the Australian flu strain, 85 people have already died and according to specialists, this is only the beginning.


What is the Australian flu- aka the H3N2 influenza A strain?

Despite prevailing belief, there is no one flu virus. There are actually four closely related viruses, that we have umbrellaed under the term “flu”; influenza A, B, C and D.

When we worry about “the flu” we tend to be talking about influenza A and influenza B. Influenza D is especially found in pigs and cows but cannot infect humans.

Influenza A is the most common type of flu and can be a danger to young children and the elderly. It has been known to be transferred between animals and humans, for example, bird flu and swine flu were both influenza A viruses.

Individual influenza A and B strains are often called after the proteins they carry on their surface – hemagglutinin (H) and neuraminidase (N). These Hs and Ns are continuously changing, hence why year-on-year each winter we come across new types of flu strains circulating. This also explains why we get re-infected every year.

The term Aussie flu or Australian flu refers to one kind of influenza A virus strain, the H3N2 strain. It was dubbed the Australian flu following its damaging effects in Australia during winter 2017. It is now the latest deadly flu strain circulating around the UK.

Every year there are various flu strains that appear, however, H3N2 is having more deadly effects than others and has so far been the cause of death for 85 people in Britain since the beginning of winter 2017.

The H3N2 strain is particularly violent due to its severe symptoms, its prolonged recovery time and its tolerance to the normal flu vaccine. The CDC estimates that the flu vaccine is only 20-30% effective against the H3N2 strain.


Why is the flu vaccine only 20-30% effective against the H3N2 strain?

Although the current flu vaccine we have in the UK is good at protecting us from other strains of flu, we have not yet managed to create an effective one against H3N2. The main reason for this is that producing flu vaccines is a long and complex process.

Every year, the World Health Organisation advise what to put in that year’s flu vaccine. Each flu vaccine tends to be designed to protect against three or four strains that are particularly prominent that year. However, flu viruses mutate quickly and during the time it takes to create a vaccine, the chosen flu strains will have already evolved and developed, and often so much so that the antibodies stimulated by the vaccine are not able to protect against the virus.

Another reason for the failure of flu jabs is the way that they are currently produced. For now, the most common way of incubating the flu virus for vaccine development is in chicken eggs. However, according to GlaxoSmithKline, the H3N2 strain has been particularly difficult to incubate in eggs.

A chicken egg is a different environment to a human body, and consequently, the flu virus in the chicken egg adapts to its surroundings and mutates. Over the course of the development of the vaccine, it can become a different virus to the original flu virus. This, in many cases, makes the vaccine redundant.

These issues have made it very hard for scientists to find effective ways to control mutating flu strains like the H3N2. Various companies across the globe are looking at new and unconventional ways of creating flu vaccines altogether. Some are attempting to develop a more general flu vaccine to protect against all flu strains, as opposed to a selection.


Improving the efficiency of the flu vaccine

Seqirus, the vaccine unit of Australian manufacturer CSL, have been looking at growing the influenza virus in cells as opposed to growing the virus in chicken eggs. It is thought that this could be more effective, as growing the virus in cells is more comparable to how the virus would act naturally when it is in circulation.

Additionally, Protein Sciences, a company acquired by Sanofi last year has been manufacturing vaccines in insect cells. The next step for them is attempting to use this technique on a larger scale.

Other scientists worldwide are working on producing a vaccine against all types of flu strains. This would avoid the issue of trying to target individual flu strains and failing because the strains are constantly mutating. One vaccine to combat all flu strains would mean not having to create a new vaccine every year and would protect more people more efficiently against any flu strain.

One example of a company working on this is Vaccitech, a spin-out company from the University of Oxford’s Jenner Institute. They are creating an unconventional type of vaccine that, rather than going after an antibody response, targets the bottom part of the protein on flu viruses to induce a T-cell response.


However, although the flu vaccine is a field that has seen an enormous amount of research and development over time, these clinical tests are still in progress. Vaccitech are projecting that their flu vaccine should be ready by 2023. Meanwhile, doctors and specialists are still encouraging people to get the existing flu jab despite its negatives, as it is currently our only solution and some protection is better than none.


Take a look at more industry news here

Posted in Articles, General, Industry News

Black triangle drug monitoring scheme across Europe

As reported by PMLive. The European Medicines Agency (EMA) announced their intentions to strengthen drug safety measures across the EU earlier this year. The introduction of black triangle, which is already in use in the UK, is to highlight drugs that are under additional monitoring.

This action is part of wider changes to pharmacovigilence standards that the EMA are putting into place, including the creation of a Pharmacovigilence Risk Assessment Committee (PRAC) and new controls to enable the EMA to ask for more post marketing safety and efficacy studies.

Click here to view our current list of pharmacovigilence jobs

Or click here to read the full article

Pharmacovigilence jobs  CK Clinical pharmacovigilence recruitment

Posted in General, Industry News, NewsTagged in , , , ,

Latest clinical jobs of the week – 17/09/2013

Here are our latest clinical jobs in this week:

latest clinical jobs of the week


Team Leader – Homebased

CMC Publisher – Homebased


EU Jobs:

Senior Outsourcing Manager – Switzerland

Expert Statistician Biomarkers – Switzerland

Biostatistician – France

Senior Global Data Manager – Belgium

Biostatistician – Switzerland

latest clinical jobs of the week

Clinical Operations:

Clinical Research Scientist – South of England

CRA II – Middlesex

Contracts Manager, R&D – Cambridgeshire

Clinical Site Manager, Home Based

Medical infomation & PV Jobs

Medical Science Liaison (Multiple) – Oncology – UK

latest clinical jobs of the week

Regulatory Affairs:

Regulatory Scientist – South East



Medical Advisor – Neurology – Berkshire

Director PVG – South East



If these roles are not of interest to you then please search our other jobs here

Posted in General, NewsTagged in

Launch of new Refer a Friend scheme

We are pleased to announce the launch of our Refer a Friend scheme.

The scheme rewards you with a £50 Amazon gift voucher if you refer a friend or colleague to CK Clinical and we successfully place them in a new job. Its simple!

So if you have friends or colleagues that are currently looking for work and arent registered with CK Clinical, refer them to us and we will do the rest.

For more information how it works, contact your local CK office

Terms and Conditions do apply:

The referrer needs to inform CK Clinical who referred them at the first  point of communication. The referred individual needs to be in continuous work for 3 months before the £50 Amazon will be issued

Refer a Friend scheme launched  CK Clinical Refer a Friend scheme

Posted in General, Industry News, NewsTagged in , , ,

UK Drug Prices Could be Reduced by 20%

The Europe wide reduction to healthcare spending has continued, as the UK announces the possibility of drug price reductions of up to 20 per cent.

A consultation on the revisions to the scheme which regulates branded medicine on the NHS has begun, following the recommendation of the Department of Health. The scheme is intended to control the prices of drugs outside of the Pharmaceutical Price Regulation Scheme which negotiates drug prices between industry and governments. The consultation has recommended an adjustment of between 10 and 20 per cent on sales of branded drugs to the NHS.

Lord Howe, the health minister, intends to “get the best possible outcome for all NHS patients” and that by spending more on drugs would harm other areas of NHS spending, so the reduction is beneficial overall.

Looking for a job in the medical or pharmaceutical industry? Click here, now

Novartis expects to develop 14 new blockbuster drugs by 2017    GSK hope for strong drug pipeline in 2013/2014

Posted in General, NewsTagged in

Our Latest Pharmaceutical Jobs – 28th January 2012

Are you looking for a new job in the Pharmaceutical Industry? Please click on the links below to find out about our latest pharmaceutical jobs new in this week:

Pharmaceutical jobsRegulatory Affairs jobs:

Notified Body Manager – Buckinghamshire

Regulatory Quality Manager – Hertfordshire

Regulatory Affairs Project Manager  – South East

Regulatory Operations Senior Associate – South East

Senior Manager CMC Regulatory Affairs – Hertfordshire

Senior Analyst – Regulatory Compliance – South East

DPharmaceutical jobsrug Safety jobs:

Clinical Safety Scientist – South East

Medical Information jobs:

Medical Writing Manager – Hertfordshire

Scientific Liaison Manager Neurology – South East

Biometric jobs:

Pharmaceutical jobsBiostatitical Programming Manager – Middlesex

Senior Technical Specialist – Homecounties

Clinical Operations jobs:

Senior Patient Reported Outcomes Scientist, CNS – South East

Interim Associate Director, Clinical Operations – London

Pharmaceutical jobs in Europe:

Pharmaceutical jobsExpert Clinical Manager – Switzerland

Statistical Programmer – Belgium

Program Operation Manager – Switzerland

(Senior) SAS Programmer – Germany

Global Data Manager – Belgium

Not quite what you’re looking for? Click here to register your CV with CK Clinical today.

Once registered, one of our specialist Pharmaceutical Recruitment Consultants will be in contact to discuss your requirements and any relevant pharmaceutical jobs we are recruiting for at the moment. Good luck with your job hunt.

Posted in Featured Jobs, General, News, UncategorizedTagged in , , , , , , , , , , , , , , , , , , , , , , , ,

CK Clinical Celebrate the Opening of London Office

CK Clinical, is today celebrating the opening of our new London office. With an already thriving office based in Stevenage Hertfordshire, our new London office will be the hub of our expanding recruitment operations across Europe.

This is an extremely exciting time for CK, as Priya Priya Mukherjee, European Operations Manager explains, “I am delighted to be part of the new European expansion and looking forward to taking CK Clinical to new heights across the European Pharmaceutical market.

Being based at our new central London location means we have easy access to London City Airport and Heathrow, enabling us to continue the great service we offer and meet our clients and candidates when required. We are all looking forward to the coming months and settling into our new place of work.”


The new London office will be home to a number of CK Clinical’s specialist Clinical Recruitment Consultants including:


  • Priya Mukherjee - European Operations Manager at CK ClinicalPriya Mukherjee, European Operations Manager

Priya is heading up CK Clinical’s European recruitment operations and will also be focusing on Biometrics recruitment across Europe.






  • Moin Din - Senior Recruitment Consultant at CK ClinicalMoin Din, Senior Recruitment Consultant

Moin specialises in recruiting medically qualified professionals within the pharmaceutical industry across the UK and Europe.






  • Mylene Paumier - Consultant at CK ClinicalMylene Paumier, Recruitment Consultant

Mylene specialises in recruiting for Biometrics professionals within the pharmaceutical industry across the UK and Europe.






  • Hendre Moolman - Senior Consultant at CK ClinicalHendre Moolman, Senior Recruitment Consultant

Hendre Moolman specialises in recruiting for Pharmacovigilance, Drug Safety, Medical Information and Medical Affairs professionals within the pharmaceutical industry across the UK and Europe.




The address of CK Clinical’s new London office is as follows:

CK Clinical London Office in HammersmithCrown House

72 Hammersmith Road



W14 8TH

Tel: +44 (0)207 470 5670


Posted in General, NewsTagged in , , , , , , , , , , , , , , , , , , , , , ,

GW Pharma seeks FDA approval for cannabis drug

As reported by the Daily Mail, the UK pharmaceutical company, GW Pharma is currently seeking approval from the US Food and Drug Administration (FDA) for their cannabis-based drug.

The drug, which is a mouth spray called Sativex is made from raw marijuana and is used to treat cancer pain. The drug is currently in advanced clinical trials and GW Pharma hope to receive approval by the end of the year.

Sativex is the first of it’s kind which is derived from raw marijuana – previous drugs have  used the synthetic alternatives. It contains two of marijuana’s best known components – delta 9 and cannabidiol. It ahs already been approved in New Zealand, Canada and eight European countries for the treatment of muscle spasms associated with multiple sclerosis.

Click here to search our current pharmaceutical jobs online now.

Posted in General, NewsTagged in , , , , , , , , , ,